{"name":"The HIV Netherlands Australia Thailand Research Collaboration","slug":"the-hiv-netherlands-australia-thailand-research-collaboration","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"LPV/r + TDF/FTC or TDF/3TC","genericName":"LPV/r + TDF/FTC or TDF/3TC","slug":"lpv-r-tdf-ftc-or-tdf-3tc","indication":"HIV-1 infection (treatment and prevention)","status":"marketed"},{"name":"Grazaoprevir/Elbasavir","genericName":"Grazaoprevir/Elbasavir","slug":"grazaoprevir-elbasavir","indication":"Chronic hepatitis C virus (HCV) infection, genotypes 1-6","status":"marketed"},{"name":"Grazaoprevir/Elbasavir/RBV","genericName":"Grazaoprevir/Elbasavir/RBV","slug":"grazaoprevir-elbasavir-rbv","indication":"Chronic hepatitis C virus infection (genotype 1, 4, 5, 6)","status":"marketed"},{"name":"HAART containing nevirapine","genericName":"HAART containing nevirapine","slug":"haart-containing-nevirapine","indication":"HIV-1 infection","status":"phase_2"},{"name":"LPV/r","genericName":"LPV/r","slug":"lpv-r","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"},{"name":"Lopinavir/r plus saquinavir","genericName":"Lopinavir/r plus saquinavir","slug":"lopinavir-r-plus-saquinavir","indication":"HIV-1 infection in treatment-experienced patients with protease inhibitor resistance","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"VZV vaccination","genericName":"VZV vaccination","slug":"vzv-vaccination","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"LPV/r + TDF/FTC or TDF/3TC","genericName":"LPV/r + TDF/FTC or TDF/3TC","slug":"lpv-r-tdf-ftc-or-tdf-3tc","phase":"marketed","mechanism":"This combination antiretroviral regimen suppresses HIV replication by inhibiting viral protease and reverse transcriptase enzymes simultaneously.","indications":["HIV-1 infection (treatment and prevention)"],"catalyst":""},{"name":"Grazaoprevir/Elbasavir","genericName":"Grazaoprevir/Elbasavir","slug":"grazaoprevir-elbasavir","phase":"marketed","mechanism":"Grazoprevir inhibits hepatitis C virus NS3/4A protease while elbasavir inhibits NS5A protein, blocking viral replication.","indications":["Chronic hepatitis C virus (HCV) infection, genotypes 1-6"],"catalyst":""},{"name":"Grazaoprevir/Elbasavir/RBV","genericName":"Grazaoprevir/Elbasavir/RBV","slug":"grazaoprevir-elbasavir-rbv","phase":"marketed","mechanism":"Grazoprevir inhibits hepatitis C virus NS3/4A protease while elbasavir inhibits NS5A protein, and ribavirin acts as a nucleoside analog to inhibit viral replication.","indications":["Chronic hepatitis C virus infection (genotype 1, 4, 5, 6)"],"catalyst":""},{"name":"HAART containing nevirapine","genericName":"HAART containing nevirapine","slug":"haart-containing-nevirapine","phase":"phase_2","mechanism":"Non-nucleoside reverse transcriptase inhibitor","indications":["HIV-1 infection"],"catalyst":""},{"name":"LPV/r","genericName":"LPV/r","slug":"lpv-r","phase":"marketed","mechanism":"LPV/r is a combination of lopinavir and ritonavir that inhibits HIV protease, preventing the maturation of HIV virions and blocking viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients","HIV-1 infection in pregnant women"],"catalyst":""},{"name":"Lopinavir/r plus saquinavir","genericName":"Lopinavir/r plus saquinavir","slug":"lopinavir-r-plus-saquinavir","phase":"marketed","mechanism":"This combination of two protease inhibitors blocks HIV protease to prevent viral replication, with ritonavir boosting lopinavir levels.","indications":["HIV-1 infection in treatment-experienced patients with protease inhibitor resistance"],"catalyst":""},{"name":"VZV vaccination","genericName":"VZV vaccination","slug":"vzv-vaccination","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE41cWtvZnlPbVVkNXVzalQ0WHlWY0RFUjZjd0ZQYzRqZk45MFJ3YTN1QndPaDhwZlVjMDFCekdlQ2ZVRDVpTEtSeVAxOVpXM2E2TXpHeEpHYi1sOHFqd0dN?oc=5","date":"2023-09-02","type":"pipeline","source":"nature.com","summary":"Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection - nature.com","headline":"Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxONlpkd0VyNUNZNlZsSFU3WHEzRjhRR0tWY2ZZRjVjR3dRd2pRLW9lX2VsUVU1WmlCakNxNk5icU9sQU5fejFBN19VQWo5WDRZZGVyY1hsdUM1V0pGdldRVTBrX0piTkljRHhSeDJCV2NuZ3VLS0NuS0tHMUZSYXp2N0JuWkx5bzJzN1RpbjBLdktXNzNUTzJ0UA?oc=5","date":"2020-01-17","type":"pipeline","source":"UNAIDS","summary":"Turning the tide of the HIV epidemic in Thailand - UNAIDS","headline":"Turning the tide of the HIV epidemic in Thailand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQMDFsOXJnYzZUYnNGOGlvTkxESDZtaFVwZzNETkJzU01aZF9ZUHhvOXZLQkZpVGx5YmpQZzFfYnFkTTFvcHlGVjYySG5qbHF4N3UzMklTNERFWG1SNGQyYmdmNFAzS1FpQzFsc1VvSy02UkN3aFRHaUMwdGZ2LUplVTdMNGs2SENiWmRV?oc=5","date":"2014-07-23","type":"pipeline","source":"The Lancet","summary":"Joep Lange - The Lancet","headline":"Joep Lange","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOMTVBeG5lZE9kdU9hQ2NreVoyTVJsdi1xUnF4d0xFSW9wdnRTVVplM21PbUJaN01LVFROc0Q5cl9COTVNaFZIS2tCYVRIa1NFa3Q3WkhNdTEzQ0loS196ZHNpWWo5c0FDc3ZkZmtfd2VVTW14SWQ4OHFNT2J4RkRzSzZqeE0xSFpFaEdaTV9XeENIN00?oc=5","date":"2014-07-19","type":"pipeline","source":"Los Angeles Times","summary":"Pioneering AIDS researcher Lange was a star with a passion to help - Los Angeles Times","headline":"Pioneering AIDS researcher Lange was a star with a passion to help","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOTmFYN0h0UUFiLVcya2hPMXdiSVptbF95NDZCQm1VSzMzSDRraDRPYmQxUTJuN05RRUxpOHRFWnFTTFZva3J3WGZtWmNfM0FaaUh5NmoxZXpsT2x2UEVyVEd0NmwybXRKWU5PTkNCd0d4NDlMdzQzZG8wZm8yeUZVVEF3VUdyS1gzQy05dkFTV3hXbVRQMkRpWnpzcjY?oc=5","date":"2014-07-18","type":"pipeline","source":"The Conversation","summary":"Joep Lange: a brave HIV researcher, a great friend and colleague - The Conversation","headline":"Joep Lange: a brave HIV researcher, a great friend and colleague","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"marketed":6,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}